Drug General Information
Drug ID
Former ID
Drug Name
Ciprofloxacin XR
ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy
Drug Type
Small molecular drug
Indication Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] Approved [1]
Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved [2]
Biliary cancer [ICD-11: 2E92.7; ICD-10: D13.4] Phase 1 [3]
Depomed Bayer


Canonical SMILES
CAS Number
CAS 85721-33-1
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Bacterial DNA gyrase (Bact gyrase) Target Info Modulator [4], [5]
Bacterial Penicillin binding protein (Bact PBP) Target Info Inhibitor [2]
Candida Thymidylate synthase (Candi TMP1) Target Info Inhibitor [6]
Staphylococcus Topoisomerase IV (Stap-coc parC) Target Info Modulator [4], [5]
BioCyc Pyrimidine deoxyribonucleotides biosynthesis from CTP
Pyrimidine deoxyribonucleotides de novo biosynthesis
Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis
Superpathway of pyrimidine deoxyribonucleoside salvage
DTMP de novo biosynthesis (mitochondrial)
Pyrimidine deoxyribonucleosides salvage
KEGG Pathway Pyrimidine metabolism
One carbon pool by folate
Metabolic pathways
Panther Pathway De novo pyrimidine deoxyribonucleotide biosynthesis
Formyltetrahydroformate biosynthesis
Pathwhiz Pathway Pyrimidine Metabolism
Pathway Interaction Database E2F transcription factor network
Reactome E2F mediated regulation of DNA replication
Pyrimidine biosynthesis
G1/S-Specific Transcription
WikiPathways Trans-sulfuration and one carbon metabolism
Retinoblastoma (RB) in Cancer
One Carbon Metabolism
Integrated Pancreatic Cancer Pathway
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in leukocytes - TarBase
miR-targeted genes in epithelium - TarBase
Metabolism of nucleotides
Fluoropyrimidine Activity
REF 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 2 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
REF 3 Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol. 2006 Jan;57(2):171-9.
REF 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF 5 DOI: 10.1093/jac/48.4.479
REF 6 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.